News Releases

November 10, 2016
Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia
First Live  E. Coli  Nissle Bacterium Modified to Assimilate Ammonia Potential Treatment of Urea Cycle Disorders and Other Forms of Hyperammonemia CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
September 12, 2016
Synlogic Expands Leadership Team to Support Rapid Advancement of the First Synthetic Biotic Towards the Clinic
Company Appoints Seasoned Biotech Executives to Lead Finance, Clinical, Translational and Manufacturing Functions September 12, 2016 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
August 29, 2016
Synlogic Proprietary Synthetic Biotic Receives FDA Orphan Drug Designation
The Company Has Developed The First Live  E. Coli  Nissle Bacterium Modified To Assimilate Ammonia For The Potential Treatment Of Urea Cycle Disorders CAMBRIDGE, Mass.–( BUSINESS WIRE )–Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
March 23, 2016
Synlogic Appoints an Industry Leader Nick Leschly to its Board of Directors
CAMBRIDGE, Mass., – March 23, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced the expansion of its Board of Directors with the appointment of Mr....
February 17, 2016
Synlogic Secures $40 Million in Series B Financing
Additional funding to accelerate the two lead Urea Cycle Disorder and Phenylketonuria pipeline programs to the clinic and expand the Synthetic Biotics platform CAMBRIDGE, Mass., – February 17, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its...
February 10, 2016
Synlogic Announces First Industry Collaboration to Develop a New Class of Medicines Designed to Power the Microbiome
Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease  CAMBRIDGE, Mass., – February 10, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and the...
January 5, 2016
Synlogic to Present at the 34th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., – January 5, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced that J.C. Gutiérrez-Ramos, Ph.D., Chief Executive Officer of Synlogic will present at a...
September 17, 2015
Synlogic Accelerates Business Growth with Appointment of President, Expansion of Financing, and an Industry Collaboration
Bharatt Chowrira, Ph.D., J.D., appointed as Synlogic’s President bringing industry expertise in corporate development, strategy, intellectual property and financing Two proprietary rare disease programs being advanced into clinical development with accelerated financing An R&D collaboration...
June 11, 2015
Synlogic to Present at Several Upcoming Scientific and Industry Conferences
In vivo efficacy data will be presented for two lead therapeutic programs in development to treat rare genetic metabolic disorders   CAMBRIDGE, Mass. – June 11, 2015  – Synlogic, Inc., a biotechnology company pioneering the development of therapeutic synthetic life, today announced that...
May 21, 2015
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
Accomplished drug hunter takes helm of synthetic biology leader as company advances lead therapeutic microbe programs toward clinical testing and executes path to drug discovery platform expansion Company debuts rare disease focused pipeline with two programs directed at genetic metabolism...
October 7, 2014
Synlogic Secures $5 Million Investment in Series A Funding Round
Bill & Melinda Gates Foundation Joins Previously Announced Series A Financing Paul Miller Ph.D. and Alison Silva join Synlogic Leadership Team CAMBRIDGE, Mass. – October 7, 2014  – Synlogic, Inc., a biotechnology company focused on the development of therapeutic microbes, today announced...
July 22, 2014
Synlogic Secures $29.4 Million Series A Financing Led by Atlas Venture and New Enterprise Associates
First-in-class, proprietary synthetic biology platform leveraged for application across multiple diseases CAMBRIDGE, Mass. – July 22, 2014  – Synlogic, Inc., a biotechnology company focused on the development of therapeutic microbes, today announced the company raised $29.4 million in a Series...
Displaying 109 - 120 of 120